"Preliminary estimates released by the Centers for Disease Control and Prevention indicate that the number of Americans diagnosed with Lyme disease each year is around 300,000. The preliminary estimates were presented Sunday night in Boston at "...
- Do not concomitantly use disinfectants containing quaternary ammonium salts for skin preparation because hyaluronic acid can precipitate in their presence.
- Anaphylactoid and allergic reactions have been reported with this product. See Adverse Events Section for more detail.
- Transient increases in inflammation in the injected knee following Hyalgan® (hyaluronate) injection in some patients with inflammatory arthritis such as rheumatoid arthritis or gouty arthritis have been reported.
- The effectiveness of a single treatment cycle of less than 3 injections has not been established.
- The safety and effectiveness of the use of Hyalgan® (hyaluronate) in joints other than the knee have not been established.
- he safety and effectiveness of the use of Hyalgan® (hyaluronate) concomitantly with other intra-articular injectables have not been established.
- Use caution when injecting Hyalgan® (hyaluronate) into patients who are allergic to avian proteins, feathers, and egg products.
- Strict aseptic administration technique must be followed.
- STERILE CONTENTS. The vial/syringe is intended for single use. The contents of the vial must be used immediately once the container has been opened. Discard any unused Hyalgan® (hyaluronate) .
- Do not use Hyalgan® (hyaluronate) if the package is opened or damaged. Store in the original packaging (protected from light) below 77° F (25°C). DO NOT FREEZE.
- Remove joint effusion, if present, before injecting Hyalgan® (hyaluronate) .
Information for Patients
- Provide patients with a copy of the PATIENT INFORMATION prior to use.
- Transient pain and/or swelling of the injected joint may occur after intra-articular injection of Hyalgan® (hyaluronate) .
- As with any invasive joint procedure, it is recommended that the patient avoid any strenuous activities or prolonged (i.e., more than 1 hour) weight-bearing activities such as jogging or tennis within 48 hours following the intra-articular injection.
Use in Specific Populations
- Pregnancy: Teratogenic Effects- Reproductive toxicity studies, including multigeneration studies, have been performed in rats, and rabbits at doses up to 11 times the anticipated human dose (1.43 mg/kg per treatment cycle) and have revealed no evidence of impaired fertility or harm to the experimental animal fetus due to intra-articular injections of Hyalgan® (hyaluronate) . Animal reproduction studies are not always predictive of human response. The safety and effectiveness of Hyalgan® (hyaluronate) have not been established in pregnant women.
- Nursing Mothers: It is not known if Hyalgan® (hyaluronate) is excreted in human milk. The safety and effectiveness of Hyalgan® (hyaluronate) have not been established in lactating women.
- Pediatrics: The safety and effectiveness of Hyalgan (hyaluronate) ® have not been demonstrated in children.
Last reviewed on RxList: 12/15/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Hyalgan Information
Hyalgan - User Reviews
Hyalgan User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options